At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
In Brief
A clinical study evaluating Oxytocin and Inactive placebo nasal spray for Schizophrenia. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been found to be critical in predicting multiple aspects of community functioning. There are no currently available medications that have been consistently found to improve social cognition in individuals with schizophrenia. Oxytocin functions as a neurotransmitter that is thought to be involved in multiple aspects of social behavior and related emotions. In this study, we test the hypothesis that acute administration of intranasal oxytocin will improve social cognition in individuals with schizophrenia.
Study Details
Timeline
Interventions
Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.